Noda S, Masumi S, Moriyama M, Kannan Y, Ohta M, Sugano T, Yamate J
Toxicology Laboratory, Pharmaceutical Research Center, Kanebo Ltd., Osaka, Japan.
Hepatology. 1996 Aug;24(2):412-8. doi: 10.1053/jhep.1996.v24.pm0008690413.
The response of hepatic macrophages and the effects of platelet-activating factor (PAF) in perfused liver were studied during production of experimental cirrhosis induced by thioacetamide (TAA) in female Sprague-Dawley rats. Within 4 weeks of TAA administration (300 mg/L drinking water), an increase in hepatic macrophage population and enlargement in cell size preceded the alterations characteristic of cirrhosis. During 12 weeks of TAA administration, the changes in hepatic macrophages were maintained and cirrhosis of the micronodular type developed with a marked increase in hydroxyproline content. Although TAA treatment for 4 weeks had no effect on oxygen consumption or hepatic portal pressure in the perfused liver, the increment in hepatic portal pressure and decrement in oxygen consumption induced by PAF in TAA-treated rats were double those in control rats. The amounts of prostaglandin D2 (PGD2) and thromboxane B2 (TxB2) in perfusate induced by PAF were seven- and fivefold greater, respectively, in TAA-treated rats than in control rats. Zymosan mimicked the effects of PAF. These results are consistent with the hypothesis that hepatic macrophages and PAF play important roles in the development of cirrhosis induced by TAA.
在雌性斯普拉格-道利大鼠中,研究了硫代乙酰胺(TAA)诱导实验性肝硬化过程中肝巨噬细胞的反应以及血小板活化因子(PAF)在灌注肝脏中的作用。在给予TAA(300 mg/L饮用水)的4周内,肝巨噬细胞数量增加和细胞大小增大先于肝硬化的特征性改变出现。在给予TAA的12周内,肝巨噬细胞的变化持续存在,并且出现了微结节型肝硬化,羟脯氨酸含量显著增加。虽然给予TAA 4周对灌注肝脏的耗氧量或肝门静脉压力没有影响,但PAF诱导的TAA处理大鼠的肝门静脉压力升高和耗氧量降低是对照大鼠的两倍。PAF诱导的灌注液中前列腺素D2(PGD2)和血栓素B2(TxB2)的量,TAA处理大鼠分别比对照大鼠高7倍和5倍。酵母聚糖模拟了PAF的作用。这些结果与肝巨噬细胞和PAF在TAA诱导的肝硬化发展中起重要作用的假设一致。